On average, HNECs derived from CRSwNP patients showed an average 1.55-fold TMPRSS2 reduction in expression compared with control patients across Th2 and Th17 cytokine treatments (HSD p-value = 0.04) and a 1.52-fold reduction in expression compared with CRSsNP patients (HSD p-value = 0.027) (Figure 6B), when controlling for the cytokine treatment group. Here, TMPRSS2 is linked to chronic rhinosinusitis with nasal polyps.